CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
sterotatic body radiotherapyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06408753
NCT06408753N/ACompleted
CompareCT.gov

Plasma Biomarker in Predicting Response and Toxicity in Hepatocellular Carcinoma Patients Treated With Checkpoint Inhibitors With or Without Sterotatic Body Radiotherapy

The University of Hong Kong·observational·Posted May 10, 2024·Updated May 10, 2024

In Brief

An observational study evaluating sterotatic body radiotherapy for Hepatocellular Carcinoma Non-resectable and Stereotactic Body Radiotherapy. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This is a prospective study to investigate the biomarkers in predicting treatment outcome and toxicity in hepatocellular carcinoma (HCC) patients receiving immune checkpoint inhibitors with or without stereotactic body radiotherapy (SBRT).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma Non-resectable, Stereotactic Body Radiotherapy
CountriesHong Kong
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 10, 2024
Enrollment StartNov 1, 2019
Primary CompletionNov 30, 2023
Study CompletionMar 27, 2024
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 2.1 years ago

Interventions

sterotatic body radiotherapyprocedure

checkpoint inhibitors with or without sterotatic body radiotherapy